Literature DB >> 23778269

The utility of copeptin in the emergency department for non-ST-elevation myocardial infarction rapid rule out: COPED-MIRRO study.

Pere Llorens1, Miquel Sánchez, Pablo Herrero, Francisco J Martín-Sánchez, Pascual Piñera, Oscar Miró.   

Abstract

OBJECTIVE: To evaluate whether the addition of copeptin measurement to the first troponin determination allows non-ST-elevation acute myocardial infarction to be ruled out in patients consulting the emergency department (ED) for nontraumatic chest pain (NTCP) suggestive of acute coronary syndrome (ACS) whose first electrocardiogram and troponin determination are nondiagnostic, thereby avoiding a second determination of troponin and shortening ED stay.
METHODS: We carried out a multicentric, prospective, observational, longitudinal, cohort study. Copeptin and troponin determination was performed on arrival of the patient to the ED. We selected consecutive patients with NTCP of less than 12 h of evolution suggestive of ACS with nondiagnostic electrocardiogram and normal troponin values on arrival to the ED. A second troponin determination was performed at 6 h. The negative predictive values and the global discriminative capacity of copeptin were calculated.
RESULTS: We studied 1018 patients (66.4±14.9 years, 62.8% men), 107 (10.5%) having non-ST-elevation acute myocardial infarction. The negative predictive value of copeptin was 94.2% and was significantly greater in patients older than 70 years of age (95.1 vs. 92.6%; P<0.05), without diabetes mellitus (95.4 vs. 90.4%; P=0.01) and arriving at the ED 6 h after the onset of NTCP (97.8 vs. 93.9%; P<0.01). The area under the copeptin receiver operating characteristic curve was 0.71 (95% confidence interval: 0.65-0.76; P<0.001).
CONCLUSION: The determination of copeptin on arrival to the ED in patients with NTCP suggestive of ACS, in addition to routine troponin determination, does not allow the presence of myocardial infarction to be ruled out quickly and safely and does not avoid ED stay for a second determination of troponin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23778269     DOI: 10.1097/MEJ.0b013e3283632f8b

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  5 in total

Review 1.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

Review 2.  Copeptin testing in acute myocardial infarction: ready for routine use?

Authors:  Sebastian Johannes Reinstadler; Gert Klug; Hans-Josef Feistritzer; Bernhard Metzler; Johannes Mair
Journal:  Dis Markers       Date:  2015-04-16       Impact factor: 3.434

3.  Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study.

Authors:  Martin Möckel; Julia Searle; Christian Hamm; Anna Slagman; Stefan Blankenberg; Kurt Huber; Hugo Katus; Christoph Liebetrau; Christian Müller; Reinhold Muller; Philipp Peitsmeyer; Johannes von Recum; Milos Tajsic; Jörn O Vollert; Evangelos Giannitsis
Journal:  Eur Heart J       Date:  2014-04-30       Impact factor: 29.983

Review 4.  Copeptin-marker of acute myocardial infarction.

Authors:  Martin Möckel; Julia Searle
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

5.  Diagnostic accuracy of copeptin sensitivity and specificity in patients with suspected non-ST-elevation myocardial infarction with troponin I below the 99th centile at presentation.

Authors:  Jonathan Duchenne; Stéphanie Mestres; Nicolas Dublanchet; Nicolas Combaret; Geoffroy Marceau; Laurent Caumon; Laurent Dutoit; Sylvie Ughetto; Pascal Motreff; Vincent Sapin; Jeannot Schmidt
Journal:  BMJ Open       Date:  2014-03-24       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.